Current approaches to periprocedural anticoagulation treatment in patients undergoing atrial fibrillation ablation
https://doi.org/10.15829/1560-4071-2019-4-68-77
Abstract
Catheter ablation is a standard treatment for patient with symptomatic and drugrefractory atrial fibrillation. As for every invasive approach, ablation is associated with certain risk of complications. About 2-3% of adverse events are related to hemorrhage or thromboembolism. Therefore, periprocedural anticoagulation scheme is of paramount importance to minimize the risk of both types of complications. Here we describe the factors, associated with thromboembolic and bleeding risks, and the evolving approaches for periprocedural anticoagulation treatment. Special attention is paid to uninterrupted oral anticoagulation and potential role of reverse agent in management of procedure-related hemorrhages.
About the Authors
N. Z. Gasymova
Almazov National Medical Research Centre
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
E. N. Mikhailov
Almazov National Medical Research Centre;
Pavlov First Saint Petersburg State Medical University;
Saint-Petersburg Electrotechnical University “LETI”
Russian Federation
Saint-Petersburg
Russian Federation
Saint-Petersburg
References
1. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm.2017;14(10):e275-444. doi:10.1016/j.hrthm.2017.05.012.
2. Raatikainen MJP, Arnar DO, Merkely B, et al. The EHRA White Book Europace. 2017;1;19(suppl_2):ii1-ii90. doi:10.1093/europace/eux258.
3. Marrouche NF, Brachmann J, Andresen D, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure N Engl J Med. 2018;378(5):417-27. doi:10.1056/NEJMoa1707855.
4. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-962. doi:10.1093/eurheartj/ehw210.
5. Sulimov VA, Golicyn SP, Panchenko EP, et al. Diagnosis and treatment of atrial fibrillation. Russ J Cardiol. 2013;18(4),S3:5-100. (In Russ.) doi:10.15829/1560-4071-2013-4s3-5-100.
6. Mikhailov EN, Gasymova NZ, Bayramova SА, et al. Clinical characteristics of patients and results of catheter ablation in atrial fibrillation in Russia: subanalysis of the European registry 2012-2016. Russian Journal of Cardiology. 2018;(7):7-15. (In Russ.) doi:10.15829/1560-4071-2018-7-7-15.
7. Cappato R, Calkins H, Chen S-A, et al. Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3(1):32-8. doi:10.1161/CIRCEP.109.859116.
8. Gupta A, Perera T, Ganesan A, et al. Complications of Catheter Ablation of Atrial Fibrillation. Circ Arrhythm Electrophysiol. 2013;6(6):1082-8. doi:10.1161/CIRCEP.113.000768.
9. Deneke T, Jais P, Scaglione M, et al. Silent cerebral events/lesions related to atrial fibrillation ablation: a clinical review. J Cardiovasc Electrophysiol. 2015;26(4):455-63. doi:10.1111/jce.12608.
10. Kirchhof P, Haeusler KG, Blank B, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018;39(32):2942-55. doi:10.1093/eurheartj/ehy176.
11. Wazni OM, Beheiry S, Fahmy T, et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation. 2007;116(22):2531-4. doi:10.1161/CIRCULATIONAHA.107.727784.
12. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol. 2012;33(2):171-257. doi:10.1007/s10840-012-9672-7
13. Cappato R, Marchlinski FE, Hohnloser SH, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015;36(28):1805-11. doi:10.1093/eurheartj/ehv177.
14. Calkins H, Willems S, Gerstenfeld EP, et al. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N Engl J Med. 2017;377(5):495-6. doi:10.1056/NEJMc1707247.
15. Kuwahara T, Abe M, Yamaki M, et al. Apixaban versus warfarin for the prevention of periprocedural cerebral thromboembolism in atrial fibrillation ablation: multicenter prospective randomized study. J Cardiovasc Electrophysiol. 2016 May;27(5):549-54. doi:10.1111/jce.12928.
16. Instructions for use of the drug for medical use Pradaxa. (In Russ.)
17. Hicks KA, Stockbridge NL, Targum SL, et al. Bleeding Academic Research Consortium Consensus Report. Circulation. 2011;123(23):2664-5. doi:10.1161/CIRCULATIONAHA.111.032433.
18. Romero J, Cerrud-Rodriguez RC, Diaz JC, et al. Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials. Europace. 2018;20(10):1612-20. doi:10.1093/europace/euy133.
19. Da Costa A, Delolme C, Guichard JB, et al. Comparison of prevalence and management of left atrial appendage thrombi under old and new anticoagulants prior to left atrial catheter ablation. Am Heart J. 2017 Nov;193:8-15. doi:10.1016/j.ahj.2017.07.016.
20. Ren J-F, Marchlinski FE, Callans DJ, et al. Increased intensity of anticoagulation may reduce risk of thrombus during atrial fibrillation ablation procedures in patients with spontaneous echo contrast. J Cardiovasc Electrophysiol. 2005;16(5):474-7. doi:10.1046/j.1540-8167.2005.40465.x.
21. Briceno DF, Villablanca PA, Lupercio F, et al. Clinical Impact of Heparin Kinetics During Catheter Ablation of Atrial Fibrillation: Meta-Analysis and Meta-Regression. J Cardiovasc Electrophysiol. 2016;27(6):683-93. doi:10.1111/jce.12975.
22. Chang RJ, Doherty TM, Goldberg SL. How does warfarin affect the activated coagulation time? Am Heart J. 1998;136(3):477-9.
23. Martin A-C, Godier A, Narayanan K, et al. Management of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation. Circulation. 2018;138(6):627-33. doi:10.1161/CIRCULATIONAHA.117.033326.
24. Lebedev DS, Mikhaylov EN. Preprocedural anticoagulation of patients before catheter ablation of atrial fibrillation: reducing the risk of complications during the intervention. Atmosfera, Novosti kardiologii. 2009:1:3-10. (In Russ.)
25. Glund S, Moschetti V, Norris S, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113(5):943-51. doi:10.1160/TH14-12-1080.
26. Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal — Full Cohort Analysis. N Engl J Med. 2017;377(5):431-41. doi:10.1056/NEJMoa1707278.
27. Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019 Feb 7. doi 10.1056/NEJMoa1814051.
28. FDA Approves Commercial Production for Bleeding Antidote Andexxa. https://www.medscape.com/viewarticle/907140 (2 Jan 2019).
29. Steffel J, Verhamme P, Potpara TS et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace. 2018;20(8):1231-42. doi:10.1093/europace/euy054.
30. Lebedev DS, Mikhaylov EN, Novikova TN, et al. Expert consensus statement of St. Petersburg branch of Russian Scientific Society of Arrhythmology on perioperative anticoagulation in patients with atrial fibrillation and/or flutter, aimed at catheter treatment of disorders heart rhythm or implantation of antiarrhythmic devices. Vestnik Aritmologii. 2016;(86):72-7. (In Russ.)
Review
For citations:
Gasymova N.Z., Mikhailov E.N. Current approaches to periprocedural anticoagulation treatment in patients undergoing atrial fibrillation ablation. Russian Journal of Cardiology. 2019;(4):68-77. (In Russ.) https://doi.org/10.15829/1560-4071-2019-4-68-77
Views:
1461
Email this article 